RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC.

ABSTRACT:

Background

Although immune checkpoint inhibitors (ICIs) have been successfully utilized in patients with non-small cell lung cancer (NSCLC), EGFR-mutated patients didn't benefit from ICIs. The underlying mechanisms for the poor efficacy of this subgroup remain unclear.

Methods

CD8⁺T cells cytotoxicity, DCs phagocytosis and immunofluorescence assay were applied to examine the immunosuppressive microenvironment of NSCLC. m⁶A RNA immunoprecipitation, luciferase assay and immunohistochemistry were used to explore the relationship between CD47 and ALKBH5 in EGFR-TKI resistant NSCLC. Autochthonous EGFR-driven lung tumor mouse model and PDXs were performed to explore the therapeutic potential of CD47 antibody and EGFR-TKI combination.

Results

We found t

SUBMITTER: Zhang W 

PROVIDER: S-EPMC11920402 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature